Table 1.
Baseline Characteristics of the Participants in the ANRS (France REcherche Nord&Sud Sida-Hiv Hépatites) 159 HIV-2 Trial (N = 30)
| Characteristic | No. (%) |
|---|---|
| Female sex | 20 (66.7) |
| Age, y, median (IQR) | 49 (46.0–52.6) |
| <35 | 1 (3.3) |
| 35–44 | 5 (16.7) |
| 45–54 | 17 (56.7) |
| 55–64 | 4 (13.3) |
| ≥65 | 3 (10.0) |
| Place of birth | |
| West Africa | 26 (86.7) |
| France | 4 (13.3) |
| HIV-2 transmission mode | |
| Heterosexual contact | 23 (76.7) |
| Transfusion | 4 (13.3) |
| Unknown | 3 (10.0) |
| Time since HIV-2 diagnosis, y, median (IQR) | 11 (7.5–13.9) |
| CDC stage (week –4) | |
| A | 26 (86.7) |
| B | 2 (6.7) |
| C | 2 (6.6) |
| Nadir CD4 count, cells/µL, median (IQR) | 351 (286.0–455.0) |
| CD4 count, cells/µL (week –4, week 0), median (IQR) | 436 (314–507) |
| <200 | 3 (10.0) |
| 200–349 | 6 (20.0) |
| 350–499 | 13 (43.3) |
| ≥500 | 8 (26.7) |
| CD4/CD8 ratio (week 0), median (IQR) | 0.9 (0.6–1.2) |
| Plasma HIV-2 RNA ≥40 copies/mL (week 0) | 20 (66.7) |
| Plasma HIV-2 RNA ≥5 copies/mL (week 0) | 23 (92.0) |
| Plasma HIV-2 RNA (week 0), log10 copies/mL, median (IQR) | 2.5 (1.8–3.2) |
| Total HIV-2 DNA (week 0) >6 copies (by PCR) | 8 (32.0) |
Data are presented as No. (%) unless otherwise indicated.
Abbreviations: CDC, Centers for Disease Control and Prevention; HIV-2, human immunodeficiency virus type 2; IQR, interquartile range; PCR, polymerase chain reaction.